Wednesday, March 14, 2018 -- Valneva SE, a fully integrated commercial stage biotech company focused on developing innovative, lifesaving vaccines, announced the initiation of a Phase I clinical trial in the U.S. to evaluate the safety and immunogenicity of VLA1553, its live-attenuated vaccine candidate against Chikungunya. The Phase I clinical trial is a randomized, observer-blinded, dose-escalation, multi-center study. It will […] The post Chikungunya vaccine enters Phase I clinical trial appeared first on Outbreak News Today.
Saturday, April 28, 2018 -- PaxVax, a leading independent specialty vaccine company, announced today the enrollment of the first patient in its Phase 2b dose-finding trial of the chikungunya virus-like particle (VLP) vaccine, building upon a Phase 2a study by the National Institutes of Health (NIH) with 400 subjects. The Phase 2b study will enroll 400 subjects to evaluate multiple dosing regimens. PaxVax expects […] The post Chikungunya vaccine: PaxVax announces the initiation of Phase 2b Trial appeared first on Outbreak News Today.
Saturday, May 05, 2018 -- PaxVax, a leading independent specialty vaccine company, announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its vaccine for the prevention of disease caused by the chikungunya virus. Chikungunya represents a significant public health need and can cause headache, muscle pain, and skin rashes, with severe, […] The post PaxVax Chikungunya vaccine receives FDA Fast Track designation appeared first on Outbreak News Today.
Tuesday, May 22, 2018 -- Scientists have identified a molecule found on human cells and some animal cells that could be a useful target for drugs against chikungunya virus infection and related diseases, according to new research published in the journal Nature. A team led by scientists at Washington University School of Medicine in St. Louis conducted the research, which was […] The post Chikungunya: Researchers identify target for treatment appeared first on Outbreak News Today.
Thursday, August 23, 2018 -- The U.S. Food and Drug Administration announced today the addition of Lassa fever, chikungunya virus disease, rabies and cryptococcal meningitis to the list of tropical diseases. Applicants who submit applications for drug or biological products to prevent or treat these diseases may qualify for a tropical disease priority review voucher (PRV). A tropical disease PRV […] The post Lassa fever, chikungunya, rabies, and cryptococcal meningitis added to FDA tropical diseases list appeared first on Outbreak News Today.
Wednesday, June 27, 2018 -- Provisional data from the Centers for Disease Control and Prevention (CDC) shows that through the first six months of 2018, 18 chikungunya cases were reported. All cases were imported, or occurred in travelers returning from affected areas. The cases were reported from 11 states– New York (5), Texas (3), New Jersey (2) and one each […] The post Chikungunya in the US, all cases imported appeared first on Outbreak News Today.
Friday, May 11, 2018 -- Fast Track program is designed to facilitate development and expedite review of therapies and vaccines to address unmet health needs... The post FDA grants fast track designation for a Chikungunya...
Wednesday, September 12, 2018 -- Older children and those with arthralgia were more likely to be infected with chikungunya virus during an epidemic in Haiti, according to study results published in Clinical Infectious Diseases.“The paper focuses on the [chikungunya virus (CHIKV)] epidemic, which hit Haiti in 2014, highlighting the importance diagnostically of joint pain as a marker for infection,” Infectious Disease News Editorial Board member J. Glenn Morris, Jr., MD, MPH&TM, professor of medicine and director of the Emerging Pathogens Institute at the University of Florida, said. “However, in terms of
Monday, May 07, 2018 -- If clinical development progresses, the PaxVax vaccine could potentially become the first vaccine approved by the FDA for the prevention of chikungunya.
Thursday, May 17, 2018 -- Chikungunya virus is a growing threat to the United States and other regions of the world as the mosquito that carries the virus expands its reach. Telltale symptoms of chikungunya infection are fever and joint pain that last about a week.
Monday, June 11, 2018 -- Themis announced today that the European Medicines Agency has granted PRIority MEdicines designation to its most advanced program in development, a vaccine to prevent chikungunya fever.
Tuesday, May 08, 2018 -- MedicalResearch.com Interview with: Lisa Danzig, MD Chief Medical Office PaxVax MedicalResearch.com: Would you briefly explain what is meant by Chikungunya infection? Whom does it primarily affect? How is it transmitted and what the complications? Response: Chikungunya is caused by the chikungunya … Continue reading →
Tuesday, March 13, 2018 -- Valneva Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya Lyon (France), March 13, 2018 - Valneva SE, a fully integrated commercial stage biotech company focused on...
Friday, May 04, 2018 -- There are currently no approved treatments or vaccines available for chikungunya, a virus transmitted through mosquito bites.
Tuesday, May 22, 2018 -- Scientists have identified a molecule found on human cells and some animal cells that could be a useful target for drugs against chikungunya virus infection and related diseases, according to new research published in the journal Nature.
Tuesday, March 20, 2018 -- Chikungunya virus has become a disease of global concern due to its potentially disabling consequences and its efficient transmission.
Monday, November 05, 2018 -- MV-CHIK showed excellent safety and tolerability and good immunogenicity, independent of pre-existing immunity against the vector. MV-CHIK is a promising candidate vaccine for the prevention of chikungunya fever, an emerging disease of global concern.